Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Andrea B ApoloDaniel M GirardiScot A NiglioRosa Nadal RiosAndre R KyddNicholas SimonLisa LeyLisa M CordesElias B A ChandranSeth M SteinbergSunmin LeeMin-Jung LeeShraddha RastogiNahoko SatoLiang CaoA Rouf BandaySalah BoudjadiMaria J MerinoAntoun ToubajiDilara AkbulutBernadette ReddHadi BagheriRene CostelloSandeep GurramPiyush K AgarwalHeather J ChalfinVladimir ValeraHoward StreicherJohn Joseph WrightElad SharonWilliam Douglas FiggHoward L ParnesJames L GulleyBiren SaraiyaSumanta Kumar PalDavid I QuinnMark N SteinPrimo N LaraDonald P BottaroAmir MortazaviPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
CaboNivo and CaboNivoIpi demonstrated clinical activity and safety in patients with multiple GU malignancies, especially clear cell RCC, urothelial carcinoma, and rare GU tumors such as squamous cell carcinoma of the bladder, small cell carcinoma of the bladder, adenocarcinoma of the bladder, renal medullary carcinoma, and penile cancer.